# Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

> **NCT00423514** · PHASE1,PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 38 (actual)

## Conditions studied

- Graft Versus Host Disease
- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** clofarabine
- **DRUG:** melphalan
- **DRUG:** mycophenolate mofetil
- **DRUG:** tacrolimus
- **DRUG:** thiotepa
- **PROCEDURE:** allogeneic bone marrow transplantation
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00423514
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11-20
- **Primary completion:** 2021-06-18
- **Final completion:** 2021-06-18
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2022-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00423514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00423514, "Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00423514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*